Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Indian drugmaker Sun (BSE: 524715) shares were buzzing in trade on the last trading day of the week to April 11, rising as ...

Leqselvi is a medicine used to treat severe alopecia areata, manufactured by Sun Pharmaceutical. The generic name of the drug ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

On Thursday, April 10, Sun Pharma announced that the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Sun Pharma said it will disclose its launch plans in due course of time. Leqselvi or deuruxolitinib is used to treat alopecia areata, an auto-immune condition that causes hair-loss, and it affects ...